Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients-Reference-Cited by-同舟云学术

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients

Published:2019-01-22 Issue:4 Volume:8 Page:e1564505
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Limagne Emeric¹,Richard Corentin¹²,Thibaudin Marion¹,Fumet Jean-David¹³,Truntzer Caroline¹,Lagrange Aurélie³,Favier Laure³,Coudert Bruno³,Ghiringhelli François¹²³⁴⁵

Affiliation:

1. Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, Dijon, France

2. Univ. Bourgogne Franche-Comté, Dijon, France

3. Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France

4. Centre de Recherche INSERM LNC-UMR1231, Dijon, France

5. Genetic and Immunology Medical Institute, Dijon, France

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1564505

Reference32 articles.

1. Colorectal Cancer Survivorship Care Guidelines

2. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges

3. Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer

4. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives;International Immunopharmacology;2024-12

2. Strategies for engineering oncolytic viruses to enhance cancer immunotherapy;Frontiers in Pharmacology;2024-09-06

3. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance;eLife;2024-08-15

4. OMIP‐105: A 30‐color full‐spectrum flow cytometry panel to characterize the immune cell landscape in spleen and tumor within a syngeneic MC‐38 murine colon carcinoma model;Cytometry Part A;2024-08-06

5. Circulating levels of galectin‐9 are a potential biomarker of survival in advanced non‐small‐cell lung cancer;Journal of Surgical Oncology;2024-07-24